May 2025
1. MUSIIME V, Bwakura-Dangarembizi M, Szubert AJ, Mumbiro V, et al
   Second-Line Antiretroviral Therapy for Children Living with HIV in Africa.
   N Engl J Med. 2025;392:1917-1932.
   

   >> Share

   
   November 2024
2. KELLEY CF, Acevedo-Quinones M, Agwu AL, Avihingsanon A, et al
   Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons.
   N Engl J Med. 2024 Nov 27. doi: 10.1056/NEJMoa2411858.
   

   >> Share

   
   August 2024
3. SHAN D, Zhang G, Du Z
   Nirmatrelvir for Adult Outpatients with Covid-19.
   N Engl J Med. 2024;391:477.
   

   >> Share

   
   July 2024
4. BEKKER LG, Das M, Abdool Karim Q, Ahmed K, et al
   Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.
   N Engl J Med. 2024 Jul 24. doi: 10.1056/NEJMoa2407001.
   

   >> Share

   
   
5. HAMMOND J, Yunis C, Fountaine RJ, Luscan G, et al
   Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.
   N Engl J Med. 2024;391:224-234.
   

   >> Share

   
   April 2024
6. HAMMOND J, Fountaine RJ, Yunis C, Fleishaker D, et al
   Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.
   N Engl J Med. 2024;390:1186-1195.
   

   >> Share

   
   January 2024
7. CAO B, Wang Y, Lu H, Huang C, et al
   Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
   N Engl J Med. 2024;390:230-241.
   

   >> Share

   
   June 2023
8. CAO Z, Gao Y, Zhao R
   VV116 or Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. Reply.
   N Engl J Med. 2023;388:2396-2397.
   

   >> Share

   
   
9. LI Y
   VV116 or Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
   N Engl J Med. 2023;388:2396.
   

   >> Share

   
   
10. EDWARDS JL
    VV116 or Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    N Engl J Med. 2023;388:2395-2396.
    

    >> Share

    
    
11. BERGMANN F, Jorda A, Zeitlinger M
    VV116 or Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    N Engl J Med. 2023;388:2395.
    

    >> Share

    
    
12. LIN DY, Fleming TR
    VV116 or Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    N Engl J Med. 2023;388:2395.
    

    >> Share

    
    
13. OMBAJO LA, Penner J, Nkuranga J, Mecha J, et al
    Second-Line Switch to Dolutegravir for Treatment of HIV Infection.
    N Engl J Med. 2023;388:2349-2359.
    

    >> Share

    
    December 2022
14. CAO Z, Gao W, Bao H, Feng H, et al
    VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    N Engl J Med. 2022 Dec 28. doi: 10.1056/NEJMoa2208822.
    

    >> Share

    
    September 2022
15. CHARNESS ME, Gupta K, Stack G, Strymish J, et al
    Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment.
    N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2206449.
    

    >> Share

    
    
16. ANDERSON AS, Caubel P, Rusnak JM
    Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.
    N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2205944.
    

    >> Share

    
    
17. PATEL K, Huo Y, Jao J, Powis KM, et al
    Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
    N Engl J Med. 2022;387:799-809.
    

    >> Share

    
    February 2022
18. RUBIN EJ, Baden LR, Morrissey S
    Audio Interview: A New Antiviral against Covid-19.
    N Engl J Med. 2022;386:e25.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share